Pacific Biosciences
PACB
PACB
150 hedge funds and large institutions have $756M invested in Pacific Biosciences in 2019 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 67 increasing their positions, 40 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less call options, than puts
Call options by funds: $ | Put options by funds: $
less funds holding
Funds holding: →
13% less capital invested
Capital invested by funds: $873M → $756M (-$116M)
24% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 25
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Holders
150
Holding in Top 10
2
Calls
$1.2M
Puts
$1.22M
Top Buyers
| 1 | +$25M | |
| 2 | +$14.7M | |
| 3 | +$10.7M | |
| 4 |
VI
Versor Investments
New York
|
+$7.65M |
| 5 |
Grantham, Mayo, Van Otterloo & Co (GMO)
Boston,
Massachusetts
|
+$6.33M |
Top Sellers
| 1 | -$12.6M | |
| 2 | -$12M | |
| 3 | -$11.8M | |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$7.75M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$7.07M |